NextCure
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of NextCure generated cash of -$52,974,000, which is more than the previous year. Cash used in financing activities reached the amount of $154,000 last year. Net change in cash is therefore -$13,548,000.
Cash Flow
| 2017 | -12.51M | -8.65M | 24.86M |
|---|---|---|---|
| 2018 | 7.99M | -3.06M | 121.41M |
| 2019 | -35.62M | -303.92M | 243.04M |
| 2020 | -44.95M | 43.52M | -1.41M |
| 2021 | -57.24M | 36.60M | -3.26M |
| 2022 | -53.88M | 67.97M | 200K |
| 2023 | -52.97M | 39.27M | 154K |
NXTC Cash Flow Statement (2017 – 2023)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|
Cash at beginning of period | 26.63M | 12.33M | 36.28M | 39.13M | 135.63M | 9.28M | 5.59M |
Operating activities | |||||||
Net income | -62.72M | -74.73M | -69.38M | -36.60M | -33.73M | -22.79M | -15.46M |
| Adjustments to reconcile net income to cash generated by operating activities: | |||||||
Depreciation and amortization | 3.68M | 4.12M | 7.19M | 3.41M | 2.68M | 1.67M | 582K |
Stock-based compensation expense | 8.18M | 9.50M | 10.28M | 7.91M | 1.88M | 0 | 75K |
| Deferred income tax benefit | 8.18M | 9.50M | 10.28M | 7.91M | 1.88M | 0 | 75K |
| Changes in operating assets and liabilities: | |||||||
Accounts receivable, net | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accounts payable | -1.94M | 2.32M | -1.95M | 2.04M | -622K | 1.34M | 767K |
Cash generated by operating activities | -52.97M | -53.88M | -57.24M | -44.95M | -35.62M | 7.99M | -12.51M |
Investing activities | |||||||
Purchases Of Investments | -73.50M | -34.64M | -156.47M | -137.12M | -300.55M | 0 | 0 |
Investments In Property Plant And Equipment | -820K | -2.11M | -2.36M | -7.13M | -3.37M | -3.06M | -8.65M |
Acquisitions Net | 0 | -70.09K | -38.96K | -50.65K | 0 | 0 | 0 |
Cash generated by investing activities | 39.27M | 67.97M | 36.60M | 43.52M | -303.92M | -3.06M | -8.65M |
Financing activities | |||||||
Common Stock Issued | 154K | 66K | 208K | 112K | 238.50M | 4K | 25M |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repayments of term debt | 0 | 0 | -3.47M | -1.52M | 4.54M | -400K | -140K |
Cash used in financing activities | 154K | 200K | -3.26M | -1.41M | 243.04M | 121.41M | 24.86M |
Net Change In Cash | -13.54M | 14.29M | -23.90M | -2.84M | -96.50M | 126.34M | 3.69M |
Cash at end of period | 13.08M | 26.63M | 12.37M | 36.28M | 39.13M | 135.63M | 9.28M |
| Data source | Data source | Data source | Data source | Data source |